ETEST TETRACYCLINE
K981134 · Ab Biodisk · JWY · May 28, 1998 · Microbiology
Device Facts
| Record ID | K981134 |
| Device Name | ETEST TETRACYCLINE |
| Applicant | Ab Biodisk |
| Product Code | JWY · Microbiology |
| Decision Date | May 28, 1998 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.1640 |
| Device Class | Class 2 |
Intended Use
For in vitro diagnostic use: Etest is a quantitative technique for the determination of antimicrobial susceptibility of both non-fastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species and fastidious bacteria, such as anaerobes, Pneumococcus and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in ug/ml of individual antibiotics against bacteria as tested on agar media by overnight incubation. This Etest 510(k) application is for MIC determination of Tetracycline in the range of 0.016 - 256 µg/ml with non-fastidious Gram positive and Gram negative aerobic bacteria, H. influenzae, N. gonorrhoeae and Streptococcus spp.
Device Story
Etest is a quantitative antimicrobial susceptibility testing device; consists of a predefined antibiotic gradient on a carrier strip; applied to agar media inoculated with bacterial samples; incubated overnight; antibiotic diffuses into agar creating a concentration gradient; elliptical zone of inhibition forms around the strip; MIC value is read directly from the strip where the zone of inhibition intersects the gradient scale; used in clinical laboratories by trained personnel; provides MIC values to guide antibiotic therapy selection; benefits patients by enabling precise dosing and effective treatment of bacterial infections.
Clinical Evidence
No clinical data provided; substantial equivalence is based on bench testing of the Etest gradient method for Tetracycline MIC determination.
Technological Characteristics
Gradient diffusion strip containing Tetracycline; concentration range 0.016-256 µg/ml; manual reading of MIC endpoint; in vitro diagnostic use; requires agar media and overnight incubation.
Indications for Use
Indicated for in vitro diagnostic determination of Minimum Inhibitory Concentration (MIC) of Tetracycline (0.016-256 µg/ml) for non-fastidious Gram-positive and Gram-negative aerobic bacteria, H. influenzae, N. gonorrhoeae, and Streptococcus spp.
Regulatory Classification
Identification
An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.
Related Devices
- K980347 — ETEST TETRACYCLINE · Ab Biodisk · May 27, 1998
- K990685 — TRIMETHOPRIM/SULPHAMETHOXAZOLE (1/19) · Ab Biodisk · Mar 26, 1999
- K980342 — ETEST CHLORAMPHENICAL · Ab Biodisk · May 29, 1998
- K982868 — ETEST RIFAMPICIN WITH INDICATIONS FOR S. PNEUMONIAE · Ab Biodisk · Sep 30, 1998
- K971697 — ETEST FOR LEVOFLOXACIN · Ab Biodisk · Jul 14, 1997
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" written around the perimeter. Inside the circle is an abstract image of what appears to be an eagle or bird in flight. The image is black and white.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 2 8 1998
Anne Bolmström President Ab Biodisk Dalvägen 10, S-169 56 Solna Sweden
Re: K981134 Trade Name: Etest® Tetracycline Regulatory Class: II Product Code: JWY Dated: March 26, 1998 Received: March 30, 1998
Dear Ms. Bolmström:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections. the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## 510(k) Number (if known): #973459/A K 98 / / 34
Device Name: Etest® Tetracycline
## Indications For Use:
For in vitro diagnostic use:
Etest is a quantitative technique for the determination of antimicrobial susceptibility of both non-fastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species and fastidious bacteria, such as anaerobes, Pneumococcus and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in ug/ml of individual antibiotics against bacteria as tested on agar media by overnight incubation.
This Etest 510(k) application is for MIC determination of Tetracycline in the range of 0.016 - 256 µg/ml with non-fastidious Gram positive and Gram negative aerobic bacteria, H. influenzae, N. gonorrhoeae and Streptococcus spp.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Woody Dubais
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K981134
Use ✗
OR
Over-The Counter Use
Prescription Use (Per 21 CFR 801.109)
(Optional Format 1-2-96)
Image /page/2/Picture/12 description: The image shows a black circle on a white background. The circle is not perfectly uniform, with some irregularities and variations in its edge. The black color of the circle is solid, and the white background provides a stark contrast. The circle is positioned in the image so that it is slightly cut off on the left side.
x